Research programme: influenza A H1N1 vaccine - Onxeo

Drug Profile

Research programme: influenza A H1N1 vaccine - Onxeo

Alternative Names: B-032; BA-032

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 06 Aug 2015 Discontinued - Preclinical for Influenza-A virus H1N1 subtype in France (Transmucosal)
  • 06 Aug 2015 Research programme: influenza A H1N1 vaccine - Onxeo is available for licensing as of 06 Aug 2015. http://www.onxeo.com/
  • 02 Sep 2014 Preclinical trials in Influenza-A virus H1N1 subtype in France before September 2014 (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top